INTRODUCTION
Traditionally, the management of patients with cancer and clinical trials in oncology have relied on tumor histopathology. 1, 2 However, analyses of genomic alterations in multiple tumor types have led to the following two fundamental observations: tumors originating in the same organ or tissue are genetically heterogeneous, 3 and similar patterns of genomic alterations may be observed in tumors from different tissues of origin. 4, 5 Furthermore, it has become clear that some of these genetic aberrations may have a significant impact on the management and prognosis of patients with cancer. [6] [7] [8] As a result, the use of genomic biomarkers to individualize cancer treatments has gained widespread acceptance in specific subsets of molecularly selected patients. 7, 9, 10 Genetic heterogeneity and the presence of similar genetic alterations across different cancer types represent both a clinical challenge and an opportunity to design new therapeutic protocols based on the genomic traits of tumors. 11, 12 However, the prevailing clinical trial design paradigms are still primarily based on tumor histopathology and were originally developed to test nontargeted cytotoxic drugs in a wide range of molecularly unselected patients. [13] [14] [15] Hence, it has become increasingly more complex to efficiently evaluate the clinical relevance of the growing number of cancer biomarkers and available targeted therapies. [16] [17] [18] Thus, new clinical trial design strategies are needed. [19] [20] [21] [22] [23] [24] One approach is the so-called basket trial design, the goal of which is to investigate the effects of targeted agents against specific molecular aberrations across multiple histologic subtypes at the same time. 25 Here, we report the results of the CUSTOM (Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies) trial (ClinicalTrials.gov identifier: NCT01306045). This trial aimed to identify molecular biomarkers and determine their frequency and clinical relevance in patients with advanced non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and thymic malignancies (TM) and to evaluate the efficacy of multiple targeted therapies in specific molecular subsets of patients.
PATIENTS AND METHODS

Molecular Profiling
The institutional review boards at the National Cancer Institute and Oregon Health and Science University approved the study before initiation of research activities. We prospectively enrolled patients with histologically confirmed recurrent or advanced NSCLC, SCLC (including lung neuroendocrine tumors 26 ), or TM to undergo molecular profiling and long-term follow-up (Data Supplement and Appendix Fig A1, online only) . Tumor samples were screened concurrently for a core set of genetic alterations that were used for experimental arm enrollment decisions and an exploratory set of molecular analyses. The core set included mutations in AKT1, BRAF, EGFR, ERBB2, HRAS, KIT, KRAS, NRAS, PDGFRA, PIK3CA, and PTEN and gene amplification in ERBB2, PIK3CA, and PDGFRA. All core assays were performed on paraffin-embedded tumor samples in Clinical Laboratory Improvement Amendments-certified laboratories. The presence of anaplastic lymphoma kinase (ALK) gene rearrangements and other potentially actionable mutations in 224 cancer-related genes was assessed with exploratory purposes.
Experimental Treatments
Patients with an EGFR mutation were screened for treatment with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Patients with KRAS, HRAS, NRAS, or BRAF mutations were screened for treatment with selumetinib, a MEK (MAPK-ERK kinase) inhibitor. Patients with mutations in PIK3CA, AKT1,orPTEN or amplification of PIK3CA were screened for treatment with MK2206, an AKT inhibitor. Patients with mutation or amplification of ERBB2 were screened for treatment with lapatinib, an ErbB2 inhibitor. Patients with mutations in KIT or PDGFRA or amplification of the latter were screened for treatment with sunitinib, a multitargeted tyrosine kinase inhibitor. Patients who did not harbor mutations in the aforementioned genes or who otherwise did not , years  18-39  13  3  0  0  17  17  30  5  40-64  253  53  43  63  55  56  351  54  Ͼ 65  215  45  25  37  26  27  266  41  Sex  Male  232  48  35  51  50  51  317  49  Female  249  52  33  49  48  49  330  51  Race/ethnicity  White  384  80  60  88  76  78  520  80  Black or AA  39  8  2  3  9  9  50  8  Asian  42  9  4  6  10  10  56  9  Other  8  2  1  1  2  2  11  2  Hispanic  9  2  1  1  1  1  11  2  Non-Hispanic  472  98  67  99  97  99  636  98  ECOG performance status  0  75  16  7  10  13  13  95  15  1  322  67  43  63  77  79  442  68  2  6 4  1 3  1 2  1 8  7  7  8 3  1 3  3-4  20  4  6  9  1  1  27  4  Histologic feature of tumor  Adenocarcinoma  363  75  0  0  0  0  363  56  Squamous cell carcinoma  64  13  0  0  0  0  64  10  Small cell   ‫ء‬   0  0  65  96  0  0  65  10  Thymoma  0  0  0  0  41  42  41  6  Thymic carcinoma  0  0  0  0  48  49  48  7  Other  54  11  3  4  9  9  66  10  Smoking history  Never-smokers  148  31  5  7  NA  NA  153  24  Current or former smokers  333  69  63  93  NA  NA  396  61 Abbreviations: AA, African American; ECOG, Eastern Cooperative Oncology Group; NA, not applicable; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
‫ء‬
Patients included in the SCLC category (n ϭ 68) included 65 patients with a clearly histologically defined SCLC and three patients (other) whose tumors were classified as lung neuroendocrine tumor.
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meet eligibility criteria for enrollment onto the targeted treatment arms were enrolled onto a not-otherwise-specified arm and were treated with either standard-of-care therapies or enrolled onto other experimental clinical trials.
Statistical Considerations
On the basis of the molecular profiling results, patients could be assigned in a nonrandomized fashion to one of five specific treatments within each tumor type (NSCLC,SCLC,andTM),addingupto15treatmentarms.Eachofthesearmswas considered independent and conducted as a phase II trial using an optimal twostage design. 27 It was hypothesized that the patient selection based on molecular alterations would result in a high objective response rate (ORR). In all arms, with the exception of EGFR mutant NSCLC, the trial was conducted to rule out an unacceptably low 10% ORR in favor of 40%. The EGFR mutant NSCLC arm aimed to rule out an unacceptably low 30% ORR (p0 ϭ 0.30) in favor of 60% (p1 ϭ 0.60), based on prior reports. 6 ,9,28 Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) from the time of treatment arm enrollment were calculated. In addition, OS curves were calculated from the time of diagnosis for all patients with NSCLC enrolled onto the study.
RESULTS
Patient Characteristics
From February 2011 to December 2012, 647 patients were enrolled and underwent molecular profiling ( Table 1 ). The most common histologic subtypes were lung adenocarcinoma (n ϭ 363, 56%), lung squamous cell carcinoma (n ϭ 64, 10%), and SCLC (n ϭ 65, 10%). For molecular profiling, archival tissue was used in 474 patients (73%), and a new fresh biopsy was obtained in 172 patients (27%). The biopsy procedures were well tolerated, and the frequency of grade 3 or 4 related complications was 3% (Appendix Table A1 , online only). A total of 569 patients (88%) had at least one molecular analysis that was successfully performed. Of these, 257 patients (45%) harbored a genetic abnormality in at least one of the core genes tested, and 23 patients (4%) harbored multiple genetic abnormalities (Fig 1) . The frequencies of the most commonly mutated genes in lung cancer are shown in Figure 2 and Table 2 . Of the patients harboring genetic abnormalities in the core genes, 212 patients (82%) were considered screen failures (Appendix Table A2 , online only), and 45 patients (18%) were enrolled onto one of the 15 treatment arms.
EGFR Mutations and Erlotinib
EGFR mutations were detected in 88 (22.1%) of 398 patients with NSCLC, one (2%) of 51 patients with SCLC, and one (1.1%) of 92 patients with TMs. These mutations were found predominantly in adenocarcinomas (n ϭ 84) and in never-smokers (43.1%). In NSCLC, 84.1% of the EGFR mutations (n ϭ 74) were known to be erlotinib sensitive (exon 19 deletions and L858R), and in 15 of these patients (20%), a resistant T790M mutation was also present (Appendix Table  A3 , online only).
Of the 90 patients who harbored mutations in EGFR, 16 (15 NSCLCs and one TM) were enrolled onto the erlotinib arm (Fig 1) . The main reason for failure to enroll onto this arm was prior erlotinib treatment. Of the 16 patients enrolled onto the erlotinib arm, 15 had evaluable disease. In patients with NSCLC, erlotinib achieved nine partial responses and an ORR of 60% (95% CI, 32.3% to 83.7%; Table  3 ). The 12-and 24-month PFS rates were 46.7% (95% CI, 24.8% to 69.9%) and 13.3% (95% CI, 3.7% to 37.9%), respectively, and the median PFS time was 11.3 months. At the time of data cutoff on March 1, 2014, the median OS time was 25.7 months, and the 12-and 24-month OS rates were 86.7% (95% CI, 62.1% to 96.3%) and 60.0% (95% CI, 33.0% to 82.1%), respectively. While running this trial, other studies had also confirmed the efficacy of erlotinib in this patient population 6, 9, 28, 29 ; therefore, we elected to close this arm before reaching the primary end point. As a result of the low frequency of EGFR mutations in SCLC and TM, complete accrual to the erlotinib arm for these tumor types was considered unfeasible.
The median OS from the time of diagnosis for all 90 patients with NSCLC harboring EGFR mutations was 3.51 years (95% CI, 2.89 to 5.50 years), and the 12-, 24-, and 36-month OS rates were 90%, 77%, and 58%, respectively. Survival times for patients with NSCLC harboring EGFR mutations were significantly longer compared with all other patients with NSCLC (Fig 3) .
RAS/RAF Mutations and Selumetinib
Mutations in KRAS were detected in 91 (24.9%) of 366 patients with NSCLC and two (4.1%) of 49 patients with SCLC (Table 2) . These mutations were found predominantly in patients with lung adenocarcinoma in whom the frequency was 27.4% (77 of 204 patients). In current or former smokers with NSCLC and lung adenocarcinoma, the frequencies of KRAS mutations were 33.5% and 40.3%, respectively, whereas in never-smokers, the frequencies were 6.8 and 5.7%, respectively. Mutations in BRAF were detected in eight 
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(2%) of 349 patients with NSCLC and one (2%) of 49 patients with SCLC. Mutations in HRAS and NRAS were present in two (0.7%) of 285 and two (0.7%) of 282 patients with NSCLC, respectively, and one (2.3%) of 43 and one (2.2%) of 46 patients with SCLC, respectively. Only two (2.4%) of 85 patients with TM were found to have an HRAS mutation; otherwise, no mutations in the RAS/RAF genes were found in patients with TMs.
Of the 110 patients with RAS/RAF mutations, 11 patients (10 with NSCLC and one with SCLC) were enrolled onto the selumetinib treatment arms (Fig 1) . In nine evaluable patients with NSCLC, selumetinib monotherapy failed to achieve its primary end point during the first stage, with only one partial response (ORR, 11%; 95% CI, 0% to 48%), a median PFS time of 2.3 months, and median OS time of 6.5 months ( Table 3) . Because of the low frequency of RAS/RAF mutations in SCLC and TM, it was considered unfeasible to complete accrual to the selumetinib arms.
The median OS from the time of diagnosis for patients with NSCLC harboring KRAS mutations was 2.30 years (95% CI, 1.74 to 3.17 years), and the 12-, 24-, and 36-month OS rates were 77%, 55%, and 45%, respectively.
ERBB2 Mutation/Amplification and Lapatinib
ERBB2 mutations were detected in eight (2.8%) of 284 patients with NSCLC, zero of 40 patients with SCLC, and zero of 85 patients with TM. These mutations were primarily found in patients with adenocarcinoma histology (n ϭ 7), and all mutations were insertions in exon 20, as previously described.
30 ERBB2 amplification was found in six (2.8%) of 211 patients with NSCLC, one (5.6%) of 17 patients with SCLC, and one (1.2%) of 84 patients with TM (Table 2) . Of the 15 patients with ERBB2 alterations, eight patients (seven with NSCLC and one with SCLC) received lapatinib (Fig 1) . Because of the low frequency of ERBB2 alterations, it was considered unfeasible to complete accrual to the lapatinib arms in all cohorts. No responses were observed in any of the patients enrolled.
PIK3CA, AKT, and PTEN Abnormalities and MK2206
PIK3CA mutations were found in 11 (3.9%) of 285 patients with NSCLC, four (8.5%) of 47 patients with SCLC, and two (2.4%) of 85 patients with TM. In patients with NSCLC, these mutations were primarily found in patients with adenocarcinoma histology (n ϭ 9). In addition, PIK3CA amplification was found in two (11.1%) of 18 KIT and PDGFRA Genetic Abnormalities and Sunitinib KIT mutations were found in one (2.6%) of 38 patients with SCLC, four (4.7%) of 85 patients with TM, and zero of 269 patients with NSCLC. PDGFRA mutations were found in one (1.2%) of 85 patients with TM and none of the patients with NSCLC (n ϭ 103) or SCLC (n ϭ 23). PDGFRA amplifications were found in five (12.8%) of 39 patients with NSCLC and none of the patients with SCLC (n ϭ 3) and TM (n ϭ 7). Because of the low frequency of KIT/PDGFRA alterations, it was unfeasible to complete accrual to this treatment arm in all cohorts. Of three patients who were enrolled onto the sunitinib arms, one partial response was observed in a patient with TM (Table 3) .
Other Genetic Abnormalities and Outcomes
Rearrangements in ALK by fluorescent in situ hybridization break-apart analysis were found in 29 (8.7%) of 335 patients with NSCLC and no patients with SCLC (n ϭ 19) or TM (n ϭ 86; Table 2 and Fig 2) . This genetic abnormality was predominately found in patients with lung adenocarcinoma (n ϭ 27), and its frequency was highest among patients who had never smoked (14.3%). The median OS time for patients with NSCLC harboring an ALK rearrangement was 2.94 years (95% CI, 1.66 to 4.61 years), and the 12-, 24-, and 36-month OS rates were 96%, 67%, and 38%, respectively. Survival in patients with NSCLC harboring ALK rearrangements was significantly better compared with the group of patients in whom no genetic abnormalities were found (Fig 3) .
Further analysis in patients with NSCLC showed strong evidence for a survival difference among five molecularly defined patient groups (Fig 3) . Patients with EGFR mutations had the longest survival times, followed by those with ALK rearrangements, KRAS mutations, and other genetic abnormalities. Patients without a molecular alteration found in one of the core genes analyzed had the shortest survival times. Treatment-related toxicities of the experimental treatments are listed in Appendix Table A4 (online only).
DISCUSSION
To our knowledge, CUSTOM is the first completed basket clinical trial to investigate the effects of targeted agents against specific molecular aberrations across multiple histologic subtypes at the same time. 15, 20, 31 A distinctive feature of the protocol design is that it allowed enrollment of patients with multiple histologic subtypes, a nonspecified number of previous therapies, and any organ function or performance status onto the molecular profiling portion of the study. As a result, we were able to enroll 647 patients in only 20 months. Consistent with other reports, 4 ,5,32 we were able to identify different subgroups of patients who were defined at the molecular level and for whom response to treatment and survival were significantly different from the overall population (ie, patients harboring EGFR 6, 9, 28 ). In addition, we were able to conduct exploratory molecular profiling analyses in uncommon cancers such as TMs and those with limited actionable genetic aberrations such as SCLC that pointed out the significant molecular heterogeneity of the different histopathology-based cancer categories and suggesting, as in previous reports, 4 ,5,33-35 that histology is an important predictor of the presence or absence of specific molecular biomarkers.
A second distinctive feature of the trial's design is that each treatment arm functioned as an independent phase II trial 27 aiming at Log-rank P < .001
Overall survival in patients with non-small-cell lung cancer stratified by mutation. A, patients harboring ALK rearrangements; E, patients harboring EGFR mutations; K, patients harboring KRAS mutations; O, patients harboring other genetic abnormalities including mutations in BRAF, ERBB2, NRAS, PIK3CA, HRAS, NRAS, PTEN, and ERBB2 amplifications; W/P/U, patients with no mutations found or unsuccessful molecular profiling.
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identifying drugs with response rates of more than 40%. Thus, only a small number of patients were needed to meet the primary end point of each arm. For instance, with only 15 patients with NSCLC harboring EGFR mutations enrolled onto the erlotinib treatment arm, this compound achieved promising results with nine partial responses and an ORR of 60%. However, with only nine evaluable patients with NSCLC harboring KRAS or BRAF mutations enrolled onto the selumetinib monotherapy arm over a period of 9 months, this drug did not meet its primary end point, with an ORR of 11%. These results are consistent with other clinical trials 9,36,37 and demonstrate the potential capability of identifying compounds with high and low clinical activity in small cohorts of molecularly selected patients by using the CUSTOM's clinical trial design.
However, our study has significant limitations, including the relatively small number of genes that were analyzed, the lack of testing of some important targets in lung cancer (ie, ROS1 rearrangements 38,39 and RET fusions, 40-42 among many others), and the fact that the molecular tests performed in each patient varied significantly as a result of the heterogeneity of the samples available for testing and the capabilities of the local testing laboratories. Furthermore, there was a significant delay in the availability of some of the core molecular profiling results, which had a significant impact in treatment arm enrollment (Table A2 ). In addition, the study was conducted at only two centers, which limited our ability to identify enough patients to successfully complete accrual to experimental arms in patients with rare histologic subtypes (ie, SCLC and TM) and patients in whom the molecular abnormalities were present at low frequencies (ie, ERBB2, PIK3CA, PTEN, AKT, KIT, PDGFRA). In contrast, even though we identified a large number of patients with NSCLC with EGFR and RAS/RAF mutations potentially eligible for enrollment, the previous use of erlotinib and the early closure of the selumetinib arm accounted for 68% of all screen failures. As a result, only 18% of potentially eligible patients harboring core genetic abnormalities were enrolled onto treatment arms, and it was not feasible to complete accrual to 13 of the 15 available arms. The lack of an adaptive design, such as that used in Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And Molecular Analysis 2 (I-SPY2) 22 or in the new Southwest Oncology Group 1400 study, in which new treatment arms can be incorporated as new drugs or molecular targets become available, was a significant weakness of CUSTOM. In retrospect, such an adaptive design would have allowed us to incorporate new arms for molecular targets that have become important (ie, ROS1 rearrangements 38,39 and RET fusions, 40-42 among many others) since the beginning of the study. In addition, such a strategy would have allowed us to add new drugs to replace selumetinib after it failed to achieve its primary end point or erlotinib once it became widely used in EGFR-mutant NSCLC, allowing us to enroll more patients with RAS/RAF or EGFR mutations in the treatment arms of the study.
Thus, although it was feasible to enroll a large number of patients and perform molecular profiling analyses at a high success rate in an innovative basket trial, the CUSTOM design seems to be unfeasible in its current form given the rarity of the selected genetic abnormalities in the populations under study. New basket trial designs should consider including a larger number of institutions and an adaptive design to successfully conduct such studies.
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